| Document |
Document Title |
|
JP3037507B2 |
PURPOSE: To prepare the new compounds each of which is useful as an intermediate for producing a pregnatrienedione type steroid compound. CONSTITUTION: The derivatives are compounds represented by the formula I (wherein: Hal is Cl or Br;...
|
|
JP3034093B2 |
PURPOSE: To obtain a catecholestrogen glycoside having improved water solubility and durability of action while maintaining inhibitory action on peroxide lipid. CONSTITUTION: A catecholestrogen glycoside of formula I (R1 is hydroxyl, glu...
|
|
JP2000504025A |
The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithel...
|
|
JP3020880B2 |
To obtain a hormonal contraceptive pill, based on natural estrogen and capable of realizing the safety of contraception in the progress of the period in the case of a lower estrogen dose and a lower gestagen dose than those of a conventi...
|
|
JP3021818B2 |
PURPOSE: To industirially advantageously obtain the compd. of the subject having 5α-reductase inhibiting activity for the treatment for acne and postatomegaly by allowing a 4,5-epoxy compd. of steroid to react with sodium azide in an in...
|
|
JP3015200B2 |
|
|
JP2000502102A |
Disclosed is a process for producing the epoxy steroid (1.0) wherein R<1> is selected from H, -OH, or C1, and R<2> is selected from hydrogen or lower alkyl. The process comprises reacting the triene of Formula (2.0) with a brominating or...
|
|
JP2000026284A |
To administer estrogen at a high rate without adding a permeation promoting agent by integrating estrogen in a matrix containing a pressure- sensitive tacky adhesive copolymer such as vinyl acetate-acrylate copolymer and delivering the e...
|
|
JP2984406B2 |
|
|
JP2974969B2 |
To obtain a medicinal matrix structure which can administer an effective does of the medicine in no need of skin penetration accelerator. The medicine is dispersed in a matrix containing a pressure- sensitively adhering acrylate copolyme...
|
|
JPH11308991A |
To economically obtain a steroid useful as a medicine or the like by incubating a sterol compound in the presence of protein(s) produced by a specific process under such conditions as to enable a steroid to be oxidized and the resulting ...
|
|
JP2972860B2 |
|
|
JP2964152B2 |
|
|
JP2963711B2 |
Genetically engineered host cells containing new expression cassettes are provided which are able to carry out biochemical oxidations of steroids. In particular the oxidation is carried out with cells into which DNA has been introduced w...
|
|
JP2959839B2 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
JPH11269194A |
To easily crystallize at low cost the subject compound usable as e.g. an antiinflammatory agent by recrystallization of an amorphous form of p-toluoylglucosyl diflucortolone with a solvent such as ethanol or (hydrous) 1-propanol. This co...
|
|
JP2956776B2 |
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I (I) wherein Z is an oxygen atom or N-OH; R2 is alpha- or beta-position methyl or ethyl; R1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, a...
|
|
JP2953725B2 |
A 11 beta -aryl-19-norprogesterone steroid of the formula: wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5 , wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl...
|
|
JP2945505B2 |
Isomerisation esp. tachysterol cpds. into previtamin D cpds. and trans-vitamin D cpds. into cis-vitamin D cpds., under the influence of radiation, is by exposing a soln. of the organic cpd. to be converted in the presence of a non-polyme...
|
|
JPH11228420A |
To obtain the subject medicine having excellent vascularization inhibitory action and easy to synthesize by including a new 9α-fluoro-6α- methylprogesterone derivative as an active ingredient. This inhibitor includes a progesterone com...
|
|
JPH11228594A |
To obtain a new progesterone compound comprising a specific progesterone compound, having excellent arterialization inhibiting action and useful as an active ingredient, etc., for arterialization inhibitors and as a treating agent for ma...
|
|
JPH11507360A |
Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or ...
|
|
JP2911553B2 |
Compounds of the general formula I have been described in which X, R<1>, R<2>, R<3> and R<4> have the meaning stated in the description, as well as processes for the preparation thereof, pharmaceutical products containing these compounds...
|
|
JP2842690B2 |
PCT No. PCT/DE90/00329 Sec. 371 Date Mar. 11, 1991 Sec. 102(e) Date Mar. 11, 1991 PCT Filed May 7, 1990 PCT Pub. No. WO90/13558 PCT Pub. Date Nov. 15, 1990.A process is disclosed for the preparation of 21-bromo-4-pregnene-3,20-dione deri...
|
|
JP2837271B2 |
PCT No. PCT/DE90/00688 Sec. 371 Date Jul. 15, 1991 Sec. 102(e) Date Jul. 15, 1991 PCT Filed Sep. 6, 1990 PCT Pub. No. WO91/04265 PCT Pub. Date Apr. 4, 1991.A process for the production of progresterone derivatives of general formula I (I...
|
|
JP2831472B2 |
Described is a process for the regioselective dehydration of 11-hydroxy steroids using PCl5, PCl3, POCl3 or either SO2Cl2 and imidazole, or PPh3 and CCl4. The disclosed process selectively forms DELTA <9,11> steroids from either 11- alph...
|
|
JP2820698B2 |
|
|
JP2812397B2 |
New 9 alpha -hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9 alpha -hydroxyandrost-4-ene-3,17-dione. The resulting compounds are useful starting compounds in the synthesis of cortic...
|
|
JPH10265495A |
To obtain the subject compound useful as e.g. an antitumor agent by clathration of a fluoroprogesterone derivative with a cyclodextrin so as to improve absorbability of the above antineoplastic derivative by oral administration. This cla...
|
|
JPH10509458A |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
JP2788739B2 |
Ethisterone, norethisterone or the 17-carboxylates thereof are used for treating acne or androgenetic alopecia.
|
|
JP2779011B2 |
The present invention relates to specific ligands for estrogen or progestagen steroid hormone receptors which have the formula (I) in which X denotes a vinyl group substituted by a radioactive or nonradioactive halogen on the double bond...
|
|
JPH10507176A |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
JP2768864B2 |
PURPOSE: To obtain a new amine compd. as an intermediate of an amine steroid useful in the treatment of medulla spinalis injury, head injury, subarachnoid hemorrhage, asthma, muscular dystrophy, skin graft rejection, septic shock, etc. C...
|
|
JP2752507B2 |
|
|
JP2750175B2 |
|
|
JP2746041B2 |
PURPOSE: To obtain the subject derivative for therapeutic agent, etc., for bone metabolic diseases such as osteoporosis, consisting of a steroid derivative containing a phosphoric acid group and capable of making a steroid compound to ac...
|
|
JPH10503191A |
PCT No. PCT/EP95/02913 Sec. 371 Date Jan. 24, 1997 Sec. 102(e) Date Jan. 24, 1997 PCT Filed Jul. 24, 1995 PCT Pub. No. WO96/03419 PCT Pub. Date Feb. 8, 1996The present invention relates to 17 alpha -dammara compounds having immunosuppres...
|
|
JP2729320B2 |
19-Substituted progesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropriate synthetic pathways which...
|
|
JP2718834B2 |
|
|
JP2718433B2 |
A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix, formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred...
|
|
JP2708204B2 |
PCT No. PCT/FR88/00188 Sec. 371 Date Dec. 15, 1988 Sec. 102(e) Date Dec. 15, 1988 PCT Filed Apr. 19, 1988 PCT Pub. No. WO88/07986 PCT Pub. Date Oct. 20, 1988.Compound useful particularly for the treatment by targetted radiotherapy or ima...
|
|
JPH09512270A |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
JP2687209B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JP2675418B2 |
Compounds of formula (I) in which X<1>, X<2> and X<3> are hydrogen, halogen, CF3, C1-6alkyl, OH, C1-6alkoxy, CN, NO2, N(R<1>)2, CHO or CO2R<1>; A is O or S, n is 0 or 1, R<1> is H or C1-8alkyl and R<3> is alpha -H, alpha -OH, or alpha -a...
|
|
JP2675436B2 |
Invented are 3-acetic acid-steroidal compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5 alpha -reductase including using these compounds to reduce prostate size and ...
|
|
JP2660413B2 |
Compounds (I): in which: R1 is hydrogen or methyl, R2 is methyl or ethyl, the nuclei A, B, C and D carry optionally one or more double bonds and are optionally substituted by one or more functional groups or by one or more atoms or radic...
|
|
JP2660404B2 |
1. The products of formula I : see diagramm : EP0245170,P90,F1 in which R1 represents an alkynyl radical having from 2 to 8 carbon atoms optionally substituted by a radical selected from the radicals, hydroxyl, halogen, trialkylsilyl, al...
|
|
JP2610674B2 |
PCT No. PCT/US88/02429 Sec. 371 Date Jan. 30, 1990 Sec. 102(e) Date Jan. 30, 1990 PCT Filed Jul. 22, 1988 PCT Pub. No. WO89/01483 PCT Pub. Date Feb. 23, 1989.The invention involves a two step chemical transformation of a steroidal 17-cya...
|
|
JPH09118687A |
PURPOSE: To profitably and easily obtain a pharmaceutically useful steroid by a method using a new production intermediate. CONSTITUTION: This method for producing a 17α-hydroxy-20-oxopregnane derivative comprises converting a steroid d...
|
